Trials / Completed
CompletedNCT02162446
68Ga-OPS202 Study for Diagnostic Imaging of GEP NET
An Open-label, Micro-dosing Study to Evaluate Safety, Biodistribution, Dosimetry and Preliminary Efficacy of Two Single 68Ga-OPS202 Doses for the Diagnostic Imaging of Somatostatin Receptor-positive Gastro-entero-pancreatic Neuroendocrine Tumors (GEP NET) Using Positron-emission Tomography / Computed Tomography (PET/CT)
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- Ipsen · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the safety and tolerability of 68Ga-OPS202 used for the diagnosis of gastroenteropancreatic neuroendocrine tumors (GEP NETs).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | satoreotide trizoxetan |
Timeline
- Start date
- 2014-06-01
- Primary completion
- 2015-06-01
- Completion
- 2015-06-01
- First posted
- 2014-06-12
- Last updated
- 2019-10-02
- Results posted
- 2019-10-02
Locations
1 site across 1 country: Switzerland
Source: ClinicalTrials.gov record NCT02162446. Inclusion in this directory is not an endorsement.